Monday, 21 October 2019

Drug Discovery News

  • Mesoblast to develop neuro diseases therapies

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 11 Jun, 2012

    Singapore: Australian company Mesoblast has outlined the company's strategic plans to develop adult stem cell therapies for neurodegenerative diseases. In an update on Mesoblast's strategi...Read more

  • BMS halts Hep C drug administration

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 02 Aug, 2012

    Singapore: Bristol-Myers Squibb (BMS) has suspended study drug administration in an ongoing phase II study of BMS-986094 (formerly known as INX-189), a nucleotide polymerase (NS5B) inhibito...Read more

  • Starpharma drug targets cancer more effectively

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 29 Oct, 2012

    Singapore: Australia-based Starpharma reported significant tumor-targeting results with its proprietary dendrimer-docetaxel formulation. In recent animal studies Starpharma's docetaxel form...Read more

  • Eisai, Toyama get marketing approval for iguratimod

    Drug Discovery |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 02 Jul, 2012

    Singapore: Eisai and Toyama Chemical have received approval from Japan's Ministry of Health, Labour and Welfare to market iguratimod for the treatment of rheumatoid arthritis. Iguratimod, ...Read more

  • Jazz Pharma clocks $208 mn in Q2 2013

    Drug Discovery |  Company results | By BioSpectrum Bureau  | 0 Comment | 07 Aug, 2013

    Singapore: Jazz Pharmaceuticals reported earnings worth $208.3 million in revenue during the second quarter of 2013, an increase from $124.2 million in the same quarter of 2012. The incre...Read more

  • Charles River to acquire Galapagos at USD 179 mn

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 19 Mar, 2014

    Singapore: Charles River Laboratories is soon to acquire CRO services division of Galapagos, which includes both Argenta and BioFocus, European companies in integrated drug discovery servic...Read more

  • Chugai, Nippon Shinyaku tie up for drug development

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 06 Dec, 2012

    Singapore: Tokyo-headquartered Chugai Pharmaceutical and Kyotobased Nippon Shinyaku have entered into an agreement to co-develop and co-market GA101 (obinutuzumab), the first glycoengineere...Read more

  • EMA recommends MSD's melanoma drug

    Drug Discovery |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 27 May, 2015

    Singapore: European Medicines Agency (EMA) has recommended granting a marketing authorization for Merck Sharp And Dohme's Keytruda (pembrolizumab) as monotherapy for the treatment of adult ...Read more

  • 10 top global pharma firms join hands for drug discovery

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 20 Sep, 2012

    Singapore: Ten leading biopharmaceutical companies have formed a non-profit organization to accelerate the development of new medicines. Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-...Read more

  • Nuvilex, Lincoln Park Fund sign $27 mn stock deal

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 21 Feb, 2014

    Singapore: Nuvilex, an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, entered into a stock purchase agreement with Linco...Read more

  • Korea to spend $8.9 bn to develop 20 drugs by 2017

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 23 Jul, 2013

    Singapore: South Korea will channelize a combined $8.9 billion (10 trillion Won) on developing 20 new drugs over the next five years, and this will be done in collaboration with private loc...Read more

  • Abbott reveals 10-year study data for HUMIRA

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 06 Jun, 2012

    Singapore: Abbott revealed the results from two long-term, open-label studies, which evaluated the results of HUMIRA (adalimumab) treatment for up to 10 years in patients with long-standing...Read more

  • Edinburgh Univ, Biogen to study neuro diseases

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 22 Jul, 2013

    Singapore: Experts from University of Edinburgh, UK, and Massachusetts-based biotechnology company Biogen Idec have joined hands to seek greater insight into multiple sclerosis and motor ne...Read more

  • Admedus acquires Genzyme manufacturing site

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 12 Dec, 2013

    Singapore: Admedus, formerly Allied Healthcare, has signed a share purchase agreement to acquire an established manufacturing site from Genzyme Australasia, a Sanofi company. Admedus recei...Read more

  • AstraZeneca halts development of obesity drug

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 10 Sep, 2012

    Singapore: Palatin Technologies collaboration with AstraZeneca is to be discontinued for the further development of AZD2820, one of the many compounds that were jointly being developed for ...Read more

  • Trajenta shows blood glucose improvements

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 02 Jul, 2012

    Singapore: Results from a two-year study has demonstrated that Boehringer Ingelheim's Trajenta (linagliptin) provides similar blood glucose improvements when compared to the commonly prescr...Read more

  • One drug for three diseases

    Drug Discovery |  Opinion | By Nandita Singh | 0 Comment | 01 Aug, 2012

    VM202 is a DNA-based drug that is designed to produce two isoforms of hepatocyte growth factor (HGF) - HGF 728 and HGF 723 - when taken up by a cell. The HGF has two very important biologi...Read more

  • China invests $160 bn in biomedicine sector

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 12 Jul, 2013

    Singapore: A report filed by Lux Research that tracks emerging technologies has said that China has invested a staggering $160 billion into its biomedicine sector in an effort to catch up w...Read more



Podcast

 

Survey Box

Is Asia-Pacific dominating the global digital transformation in healthcare market?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls